about
Insulin: an emerging treatment for Alzheimer's disease dementia?Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatmentIncreasing brain protein O-GlcNAc-ylation mitigates breathing defects and mortality of Tau.P301L miceClusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathwayControl of neuronal ion channel function by glycogen synthase kinase-3: new prospective for an old kinase.Hirano bodies differentially modulate cell death induced by tau and the amyloid precursor protein intracellular domain.Phosphorylation of amyloid precursor protein at threonine 668 is essential for its copper-responsive trafficking in SH-SY5Y neuroblastoma cells.Protein tau: prime cause of synaptic and neuronal degeneration in Alzheimer's disease.Early intervention with an estrogen receptor β-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer's disease.A powerful yeast model to investigate the synergistic interaction of α-synuclein and tau in neurodegeneration.Tauopathy differentially affects cell adhesion molecules in mouse brain: early down-regulation of nectin-3 in stratum lacunosum moleculare.Neuronal apoptosis and motor deficits in mice with genetic inhibition of GSK-3 are Fas-dependentEfficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathyA pivotal role of GSK-3 in synaptic plasticity.Specific serine-proline phosphorylation and glycogen synthase kinase 3β-directed subcellular targeting of stathmin 3/Sclip in neurons.Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.Mathematical model on Alzheimer's diseasePresynaptic Aβ40 prevents synapse addition in the adult Drosophila neuromuscular junction.Prostate-derived sterile 20-like kinases (PSKs/TAOKs) phosphorylate tau protein and are activated in tangle-bearing neurons in Alzheimer disease.New insights into negative effects of lithium on sea urchin Paracentrotus lividus embryos.Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer's disease: implications for synaptic dysfunction and neuronal damageTherapeutic strategies for tau mediated neurodegeneration.GSK-3β and MMP-9 Cooperate in the Control of Dendritic Spine MorphologyNovel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesisGlycogen synthase kinase 3 inhibitors induce the canonical WNT/β-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma.Numb and Alzheimer's disease: the current pictureLithium suppression of tau induces brain iron accumulation and neurodegeneration.Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal.AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans.Molecular Chaperone Accumulation in Cancer and Decrease in Alzheimer's Disease: The Potential Roles of HSF1.Aberrant Wnt signaling: a special focus in CNS diseases.Alzheimer's disease and metabolic syndrome: A link from oxidative stress and inflammation to neurodegeneration.Tanshinone IIA protects PC12 cells from β-amyloid(25-35)-induced apoptosis via PI3K/Akt signaling pathway.Inhibition of GSK3 by lithium, from single molecules to signaling networks.Erythrocytes as Potential Link between Diabetes and Alzheimer's DiseaseBlockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease.Neurological functions of the masterswitch protein kinase - gsk-3.Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy.Eicosanoyl-5-hydroxytryptamide (EHT) prevents Alzheimer's disease-related cognitive and electrophysiological impairments in mice exposed to elevated concentrations of oligomeric beta-amyloid.
P2860
Q26827376-5A4B10C3-4D79-4943-BA47-04A3E2FD1683Q26860246-5C4A97BB-A52F-4ADE-892A-445F19B10B94Q28537913-C7F56B9C-C1B7-43EE-A3B9-09B324BE7DBEQ29870999-EB6AFA29-D1D8-492D-BDFD-0F9F06634315Q30465622-7096B774-B293-46D8-8A11-7BD88736566AQ31165645-62D1FE8F-B140-47E2-ABBB-D21B7EAD5353Q33676177-F09131AC-BB98-416F-A23A-40377732AF30Q34283149-9253E377-6028-407E-920B-4B969095FEE0Q34342779-3792AA9C-A150-48DA-8C75-C9D791999F40Q34581042-31C91150-7F22-459E-868A-959827959590Q34737538-11928CA1-9FD6-4D36-9EAB-514F845AC951Q34936432-96042D93-735D-42E6-8887-23A4C1349378Q34973787-C041C7E9-337D-4678-BBCD-86DB45E1759BQ35757839-E72A1176-93E5-4400-AB50-5EF9E91397BDQ36052564-43154F05-E381-4416-A25A-E69390A750E5Q36142754-9C2083D8-609C-41D4-95F9-19A9B1A926B0Q36198218-7BB04669-9C72-4108-9751-CE65D788A079Q36375613-0EE68A4C-BC76-47F9-BC6A-A2873C194D2FQ36873750-29C58642-34CA-43FF-BBD1-BD99D7AE165FQ37209141-A122ACC2-D7AE-473F-9540-3392572042DEQ37302845-B0F4E17F-D225-4FA1-8EBC-CE0387521BBEQ37550818-9D7ABA1C-F1E4-4132-A61C-DB23C47C1AE4Q37569915-B36AAF1A-7737-403B-96FD-D63439BC3C49Q37610545-814038DA-7148-4AB8-9928-49437DA4506CQ37690524-57ABA3BB-E531-4266-9DA0-964E505BB0FAQ37702007-8B065CBD-A7F6-4737-BDAF-5199289502C4Q38051625-1506FA12-5901-4CA3-A260-F79049A97A08Q38412707-A74D6C58-48A8-49CC-816E-8F1F4443C9B9Q38994300-96504C86-07DD-472E-AFE0-2A10CC8615EBQ39194419-4CEE8C7F-8369-4B62-9357-97BF58B3A648Q39292455-275684F8-43E7-4848-838E-6D6FCF6903FBQ39387696-B703A861-C773-4EC0-80B6-C65A69FD6A82Q39398227-3268DF06-4BFB-41DE-9298-4A03503BA30FQ39399964-4AA8F726-7C05-410C-8A57-5FFB052F9E72Q41285005-3DE797D4-ED5A-4FCE-BA1D-2B6F0DA0C0E1Q41547214-69105108-98F5-4A1A-ABBF-ABFB5C48C317Q42020086-E774757F-D9C4-49AC-9A4F-ECD8408E1FE8Q42195030-51FE235E-2C3B-45DF-9470-7D8FC59A9293Q47110701-CA6C5168-A0E2-4283-B08A-CDC9A92792E7Q47279111-3770BC91-1638-43EA-AB8F-D24E9CE48A07
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
GSK3 and Alzheimer's Disease: Facts and Fiction….
@ast
GSK3 and Alzheimer's Disease: Facts and Fiction….
@en
type
label
GSK3 and Alzheimer's Disease: Facts and Fiction….
@ast
GSK3 and Alzheimer's Disease: Facts and Fiction….
@en
prefLabel
GSK3 and Alzheimer's Disease: Facts and Fiction….
@ast
GSK3 and Alzheimer's Disease: Facts and Fiction….
@en
P2093
P2860
P356
P1476
GSK3 and Alzheimer's Disease: Facts and Fiction….
@en
P2093
Anna Kremer
Justin V Louis
Tomasz Jaworski
P2860
P356
10.3389/FNMOL.2011.00017
P577
2011-08-26T00:00:00Z